Who is sponsoring NCT00785863?

NCT00785863 is sponsored by Ullevaal University Hospital.

What condition does NCT00785863 study?

NCT00785863 studies Hyperalgesia, Secondary.

What drugs are being tested in NCT00785863?

Interventions: Placebo, Remifentanil, Ketorolac and remifentanil, Parecoxib and remifentanil.

What is the status of NCT00785863?

NCT00785863 is currently COMPLETED.

Last reviewed 2011-06-30 · How we verify

Modulation of Remifentanil-induced Analgesia and Postinfusion Hyperalgesia by Parecoxib or Ketorolac in Humans

NCT00785863 Phase 4 COMPLETED

In addition to alleviate pain there is growing evidence that µ-opioids enhance pain. This problem is known as opioid induced hyperalgesia(OIH).The NMDA receptor is involved in opioid induced hyperalgesia it may be possible to block OIH by cyclooxygenase inhibitors. This has been demonstrated with parecoxib, a COX-II inhibitor, in a experimental pain model.Both COX-1 and COX-2 are expressed in the spinal cord. It would be of interest to investigate whether a COX-1 preferring inhibitor like ketorolac also can reduce opioid induced hyperalgesic in this experimental pain model.

Details

Lead sponsor	Ullevaal University Hospital
Phase	Phase 4
Status	COMPLETED
Enrolment	16
Start date	2008-12
Completion	2009-04

Conditions

Hyperalgesia, Secondary

Interventions

Placebo
Remifentanil
Ketorolac and remifentanil
Parecoxib and remifentanil

Primary outcomes

H0 : Parecoxib prevents remifentanil postinfusion secondary hyperalgesi. Ketorolac does not prevent remifentanil postinfusion secondary hyperalgesi. — during the study

Countries

Norway